Form 4: TScan Therapeutics' Chief Medical Officer, Chrystal Louis, Acquires 380,000 Stock Options

Chrystal Louis, Chief Medical Officer of TScan Therapeutics, acquired 380,000 stock options on May 1, 2024, according to a Form 4 filing with the SEC.

Summary

• Chrystal Louis, the Chief Medical Officer of TScan Therapeutics, acquired 380,000 stock options on May 1, 2024.
• The exercise price of these options is $8.62.
• The options vest over a four-year period, with 25% vesting on the one-year anniversary of April 22, 2024, and the remaining balance vesting in equal monthly installments over the subsequent 36 months.
• The expiration date for these options is April 30, 2034.
• Following the transaction, Louis directly owns 380,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard executive compensation disclosure. The grant of options can be seen as a positive sign of confidence, but it's also a routine occurrence.

Positives

• The acquisition of stock options by a key executive like the Chief Medical Officer can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests between management and shareholders.

Stakeholder Impact

• Shareholders may view the stock option grant as an incentive for the Chief Medical Officer to drive company success, potentially increasing shareholder value.

Key Dates